Analysts Have Conflicting Sentiments on These Healthcare Companies: Healthequity (HQY), Sarepta Therapeutics (SRPT) and COMPASS Pathways (CMPS)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Healthequity (HQY), Sarepta Therapeutics (SRPT) and COMPASS Pathways (CMPS).
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Healthequity (HQY)
In a report released yesterday, Ryan Halsted from RBC Capital maintained a Buy rating on Healthequity, with a price target of $108.00. The company’s shares closed last Wednesday at $94.73.
According to TipRanks.com, Halsted is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Healthequity with a $113.50 average price target, a 17.0% upside from current levels. In a report issued on June 25, J.P. Morgan also reiterated a Buy rating on the stock with a $123.00 price target.
See today’s best-performing stocks on TipRanks >>
Sarepta Therapeutics (SRPT)
In a report issued on July 7, Brian Abrahams from RBC Capital maintained a Hold rating on Sarepta Therapeutics, with a price target of $19.00. The company’s shares closed last Wednesday at $20.21.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of
Currently, the analyst consensus on Sarepta Therapeutics is a Hold with an average price target of $23.46, which is a 18.9% upside from current levels. In a report issued on June 22, Barclays also maintained a Hold rating on the stock with a $20.00 price target.
COMPASS Pathways (CMPS)
In a report issued on July 7, Leonid Timashev from RBC Capital maintained a Buy rating on COMPASS Pathways, with a price target of $22.00. The company’s shares closed last Wednesday at $13.97.
According to TipRanks.com, Timashev is a 5-star analyst with an average return of
Currently, the analyst consensus on COMPASS Pathways is a Strong Buy with an average price target of $24.43, representing a 91.3% upside. In a report released yesterday, TipRanks – Google also upgraded the stock to Buy with a $14.50 price target.
Read More on HQY:
Disclaimer & DisclosureReport an Issue
- HealthEquity Shareholders Approve Directors and Equity Plans
- HealthEquity price target raised to $111 from $110 at Citizens
- HealthEquity Earnings Call Signals Confident Growth Path
- Midday Fly By: Dell reports blowout results, Blue Origin rocket explodes
- HealthEquity price target raised to $108 from $100 at RBC Capital
